These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 30688052)

  • 1. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.
    Lee JY; Cho Y; Lee M; Kim YJ; Lee YH; Lee BW; Cha BS; Kang ES
    Diabetes Metab J; 2019 Apr; 43(2):158-173. PubMed ID: 30688052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC
    Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
    Goldenberg RM
    Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor.
    Kusunoki M; Natsume Y; Miyata T; Tsutsumi K; Oshida Y
    Drug Res (Stuttg); 2018 Dec; 68(12):704-709. PubMed ID: 29966149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
    Yagi S; Aihara KI; Kondo T; Kurahashi K; Yoshida S; Endo I; Fukuda D; Nakaya Y; Suwaki KI; Takeji T; Wada T; Salim HM; Hama S; Matsuura T; Ise T; Kusunose K; Yamaguchi K; Tobiume T; Yamada H; Soeki T; Wakatsuki T; Matsuhisa M; Shimabukuro M; Akaike M; Sata M
    Adv Ther; 2018 Jan; 35(1):124-134. PubMed ID: 29185199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
    Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
    Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors.
    Shimizu N; Ogawa A; Hayashi A; Shichiri M
    J Diabetes Complications; 2022 Jul; 36(7):108225. PubMed ID: 35690574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
    Fushimi Y; Obata A; Sanada J; Iwamoto Y; Mashiko A; Horiya M; Mizoguchi-Tomita A; Nishioka M; Kan Y; Kinoshita T; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Res; 2020; 2020():4861681. PubMed ID: 32337293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
    Scheen AJ
    Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
    Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
    Dennis JM; Young KG; McGovern AP; Mateen BA; Vollmer SJ; Simpson MD; Henley WE; Holman RR; Sattar N; Pearson ER; Hattersley AT; Jones AG; Shields BM;
    Lancet Digit Health; 2022 Dec; 4(12):e873-e883. PubMed ID: 36427949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
    Panikar V; Joshi SR; Deogaonkar N; Vadgama J; Nasikkar N; Kamat T; Sheikh S; Jain CC; Wagle T
    J Assoc Physicians India; 2018 Dec; 66(12):46-49. PubMed ID: 31315325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
    Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
    Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
    Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
    Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol.
    Angwin C; Jenkinson C; Jones A; Jennison C; Henley W; Farmer A; Sattar N; Holman RR; Pearson E; Shields B; Hattersley A;
    BMJ Open; 2020 Dec; 10(12):e042784. PubMed ID: 33371044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database.
    Mamza J; Mehta R; Donnelly R; Idris I
    Diabetes Technol Ther; 2016 Feb; 18(2):85-92. PubMed ID: 26752504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.